Lack of Preferential Localization of Tumoral Mass in B-Cell Non-Hodgkin's Lymphoma Associated With Hepatitis C Virus Infection

Zignego, Anna Linda; Ferri, Clodoveo; Innocenti, F.; Giannini, Carlo; Monti, Monica; Bellesi, G.; Geñtilini, Paolo

doi:10.1182/blood.v89.8.3066

Cited by 12 publications

(5 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Positive associations between HCV infection and NHL risk have consistently been reported in studies conducted in Italy,22–25 Japan26, 27 and Spain,28, 29 but not in France30, 31 or Canada 32, 33. The inconsistency is likely explained in part by differences in the study design,10 and low statistical power in some of these studies 34.…”

Section: Discussionmentioning

confidence: 95%

Hepatitis C infection and risk of malignant lymphoma

Schöllkopf

Smedby

Hjalgrim

et al. 2008

Intl Journal of Cancer

View full text Add to dashboard Cite

The association between hepatitis C virus (HCV) infection and risk of malignant lymphoma remains controversial, perhaps due to small-sized studies and low prevalence of HCV in the general population. On the basis of a large Danish-Swedish populationbased case-control study, 2,819 lymphoma patients and 1,856 controls of second-generation Danish-Swedish origin were screened for HCV infection using an enzyme-linked immunosorbent assay and a confirming recombinant immunoblot assay (RIBA) test. Positive samples were tested with real-time PCR for the presence of HCV RNA. The association between HCV infection and risk of malignant lymphoma was assessed by logistic regression. When intermediate RIBA test results were interpreted as positive, anti-HCV antibody positivity was associated with a nonsignificant increased risk of non-Hodgkin lymphoma (NHL) overall (odds ratio (

show abstract

Section: Discussionmentioning

confidence: 95%

Hepatitis C infection and risk of malignant lymphoma

Schöllkopf

Smedby

Hjalgrim

et al. 2008

Intl Journal of Cancer

View full text Add to dashboard Cite

show abstract

“…Therefore, it was hypothesized that HCV may be involved in the pathogenesis of B-NHL as well [ 46 , 49 , 54 ]. This hypothesis was substantiated by several observations including the significantly high prevalence of HCV infection in NHL patients, [ 51 , 52 , 54 , 58 , 59 , 61 - 65 ] - even with a higher prevalence in Southern countries - as well as the possible resolution of the disease following viral eradication [ 66 ]. In addition, in a recent study involving about 3,000 HCV-infected patients observed during a long-term follow-up, it was shown that the annual incidence of lymphoma was 0.23% and the cumulative rate of lymphoma development after 15 years was 2.6% in both the untreated and non-responder patients with persisting infection versus 0% in treated patients achieving viral eradication, strongly suggesting that the viral eradication protects against the development of lymphoma [ 67 ].…”

Section: Introductionmentioning

confidence: 93%

“…Early after its discovery, it was shown that HCV is also a lymphotropic virus [ 46 ]. As a consequence of the lymphatic infection, several lymphoproliferative disorders (LPDs) have been associated with HCV infection [ 47 ], including mixed cryoglobulinemia (MC) and B-cell non-Hodgkin's lymphoma (B-NHL) [ 48 - 59 ].…”

Section: Introductionmentioning

confidence: 99%

Hepatitis C virus infection in the immunocompromised host: a complex scenario with variable clinical impact

et al. 2012

View full text Add to dashboard Cite

The relationship between Hepatitis C Virus (HCV) infection and immunosuppression is complex and multifaceted. Although HCV-related hepatocytolysis is classically interpreted as secondary to the attack by cytotoxic T lymphocytes against infected cells, the liver disease is usually exacerbated and more rapidly evolutive in immunosuppressed patients. This generally occurs during the immunosuppression state, and not at the reconstitution of the host response after immunosuppressive therapy discontinuation. The field of immunosuppression and HCV infection is complicated both by the different outcome observed in different situations and/or by contrasting data obtained in the same conditions, with several still unanswered questions, such as the opportunity to modify treatment schedules in the setting of post-transplant follow-up. The complexity of this field is further complicated by the intrinsic tendency of HCV infection in itself to lead to disorders of the immune system. This review will briefly outline the current knowledge about the pathogenesis of both hepatic and extrahepatic HCV-related disorders and the principal available data concerning HCV infection in a condition of impairment of the immune system. Attention will be especially focused on some conditions - liver or kidney transplantation, the use of biologic drugs and cancer chemotherapy - for which more abundant and interesting data exist.

show abstract

“…Hepatitis C virus (HCV) infection is characterized by a high propensity to persist in the host, leading to chronic liver disease, cirrhosis and liver cancer. In the early ‘90s it was demonstrated that HCV is also a lymphotropic virus and several lymphoproliferative disorders (LPDs) have been associated with HCV infection , including B‐cell non‐Hodgkin's lymphoma (B‐NHL) and mixed cryoglobulinemia (MC) . MC is an autoimmune and lymphoproliferative disorder characterized by circulating immune‐complexes (cryoglobulins: CGs) composed of polyclonal IgGs (including anti‐HCV Ig) and mono or polyclonal IgM with rheumatoid factor (RF) activity, sustained by the clonal expansion of RF‐B cells .…”

Section: Introductionmentioning

confidence: 99%

Value of IL28B genotyping in patients with HCV‐related mixed cryoglobulinemia: results of a large, prospective study

Piluso

Giannini

Fognani

et al. 2012

Journal of Viral Hepatitis

Self Cite

View full text Add to dashboard Cite

SUMMARY. HCV-related mixed cryoglobulinemia (MC) is characterized by clonal expansion of B cells producing a polyreactive natural antibody (rheumatoid factor) and interferon (IFN)-based therapy is the first therapeutic option in mild-moderate MC. Single nucleotide polymorphisms (SNPs) proximal to genes involved in the innate response (IL28B/IFN-k gene family) are strongly associated with spontaneous and IFN-induced viral clearance in hepatitis C, but no data exist about their role in HCVpositive MC. A large cohort of patients with HCV and MC was studied to evaluate the influence of IL28B genotype on the response to treatment and/or the evolution to MC of HCV infection. The rs12979860/rs8099917 IL28B polymorphisms were analysed in 481 consecutive HCVpositive subjects (250 with MC and 231 without MC, as controls) using real-time PCR and direct sequencing. Hundred and fifteen HCV patients with MC received standard anti-HCV therapy, and the results were evaluated according to the IL28B SNP distribution. Similar IL28B SNPs allele frequencies were recorded for patients and controls. IL28B major allele homozygosis (for both SNPs tested) was tightly correlated with virological and clinical response (P = 0.002). A statistically significant association was limited to 'difficult-to-treat' (G1/4) HCV genotypes. The IL28B genotype was a strong independent predictor of response (P = 0.007, OR 6.06; CI 1.65-22.22). The IL28B genotype was confirmed to be a useful predictor of response to IFN-based therapy in patients with HCV and MC. The very close correlation between IL28B SNP distribution, virological and clinical response definitively confirmed the key role played by HCV in MC. Conversely, the IL28B genotype does not seem to influence the evolution to MC.

show abstract

Lack of Preferential Localization of Tumoral Mass in B-Cell Non-Hodgkin's Lymphoma Associated With Hepatitis C Virus Infection

Cited by 12 publications

References 8 publications

Hepatitis C infection and risk of malignant lymphoma

Hepatitis C infection and risk of malignant lymphoma

Hepatitis C virus infection in the immunocompromised host: a complex scenario with variable clinical impact

Value of IL28B genotyping in patients with HCV‐related mixed cryoglobulinemia: results of a large, prospective study

Contact Info

Product

Resources

About